← Leaderboards
Dominic James Smiraglia
Roswell Park Cancer Institute Corp
$3,001,000
Attributed
$3,290,160
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $444.3K · FY2006–20$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$3,290,160 · 4
By mechanism
R01$2,079,545 · 1
R21$1,210,615 · 3
Top collaborators
- Kenneth W Gross4 shared
- Norma Jean Nowak4 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Carl W Porter$5,047,582
- Hayley Affronti$278,317
- Lakshmi Pendyala$2,646,119
- Kenneth W Gross$7,053,357
- Barbara A Foster$3,566,345
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelGeneticCellsPathway InteractionsResponseGenesRecurrenceAndrogensPublic Health RelevanceMalignant NeoplasmsMalignant Neoplasm Of ProstateAmericanProstateNucleotidesAffectPolyamine CatabolismMetabolic PathwayGrowthAnabolismMetabolismPolyaminesCarbonEpithelial CellsEffectiveness
Grant awards (16)
Leveraging the methionine salvage pathway as a novel therapy for prostate cancer.$378,193
R01 · FY2020 · CA · contact PI
Leveraging the methionine salvage pathway as a novel therapy for prostate cancer.$370,063
R01 · FY2019 · CA · contact PI
Leveraging the methionine salvage pathway as a novel therapy for prostate cancer.$53,231
R01 · FY2019 · CA · contact PI
Leveraging the methionine salvage pathway as a novel therapy for prostate cancer.$389,441
R01 · FY2018 · CA · contact PI
Leveraging the methionine salvage pathway as a novel therapy for prostate cancer.$54,877
R01 · FY2018 · CA · contact PI
Leveraging the methionine salvage pathway as a novel therapy for prostate cancer.$389,441
R01 · FY2017 · CA · contact PI
Leveraging the methionine salvage pathway as a novel therapy for prostate cancer.$54,877
R01 · FY2017 · CA · contact PI
Leveraging the methionine salvage pathway as a novel therapy for prostate cancer.$389,422
R01 · FY2016 · CA · contact PI
Epi)Genomic drivers of primary and metastatic pancreatic islet cell carcinoma$170,128
R21 · FY2014 · CA
Epi)Genomic drivers of primary and metastatic pancreatic islet cell carcinoma$29,610
R21 · FY2014 · CA
Epi)Genomic drivers of primary and metastatic pancreatic islet cell carcinoma$213,747
R21 · FY2013 · CA
Epi)Genomic drivers of primary and metastatic pancreatic islet cell carcinoma$20,255
R21 · FY2013 · CA
Dietary Folate: Impact on Prostate Tumor Biology, Genetics and Epigenetics$210,468
R21 · FY2010 · CA · contact PI
Dietary Folate: Impact on Prostate Tumor Biology, Genetics and Epigenetics$229,580
R21 · FY2009 · CA · contact PI
CpG island methylation discovery in prostate cancer$157,540
R21 · FY2007 · CA · contact PI
CpG island methylation discovery in prostate cancer$179,287
R21 · FY2006 · CA · contact PI